Man Group plc lifted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 878.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 142,426 shares of the company's stock after purchasing an additional 127,875 shares during the quarter. Man Group plc owned 0.11% of Vaxcyte worth $11,659,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Whipplewood Advisors LLC purchased a new position in Vaxcyte during the fourth quarter valued at $28,000. Smartleaf Asset Management LLC lifted its position in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after buying an additional 260 shares in the last quarter. National Bank of Canada FI purchased a new position in shares of Vaxcyte during the 4th quarter valued at about $41,000. Blue Trust Inc. lifted its holdings in Vaxcyte by 100.0% in the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after purchasing an additional 371 shares in the last quarter. Finally, Assetmark Inc. lifted its holdings in Vaxcyte by 77,500.0% in the 4th quarter. Assetmark Inc. now owns 776 shares of the company's stock worth $64,000 after purchasing an additional 775 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.
Vaxcyte Trading Up 3.1%
Shares of PCVX stock opened at $31.85 on Monday. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06. The company has a market cap of $4.11 billion, a price-to-earnings ratio of -6.92 and a beta of 1.27. The stock has a 50 day simple moving average of $42.56 and a 200-day simple moving average of $71.47.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period in the prior year, the firm earned ($0.85) earnings per share. On average, equities analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.
Insider Activity at Vaxcyte
In related news, CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $83.85, for a total transaction of $670,800.00. Following the completion of the transaction, the chief financial officer now owns 109,491 shares in the company, valued at $9,180,820.35. The trade was a 6.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 3.10% of the company's stock.
Analyst Ratings Changes
PCVX has been the topic of several recent research reports. Guggenheim reaffirmed a "buy" rating and set a $160.00 price objective on shares of Vaxcyte in a report on Wednesday, March 12th. Bank of America lowered their target price on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. The Goldman Sachs Group decreased their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Needham & Company LLC reiterated a "buy" rating and issued a $90.00 price target on shares of Vaxcyte in a research note on Tuesday, April 8th. Finally, Cantor Fitzgerald initiated coverage on Vaxcyte in a report on Tuesday, April 22nd. They issued an "overweight" rating on the stock. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $136.50.
Check Out Our Latest Analysis on PCVX
About Vaxcyte
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
